{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:42:30Z","timestamp":1792539750995,"version":"4.5.0"},"reference-count":40,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":198,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23HL150232"],"award-info":[{"award-number":["K23HL150232"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BioMed Research International"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p><jats:italic>Background<\/jats:italic>. Sickle cell disease (SCD) is a hemoglobinopathy with increasing global prevalence resulting in pain episodes and multiorgan complications. Complications of SCD have been shown to adversely impact health\u2010related quality of life (HRQOL) comprised of physical, social, and emotional domains; hence, HRQOL measures can serve as an effective evaluator of disease burden. Hydroxyurea (HU) and other disease\u2010modifying therapies have demonstrated to significantly improve clinical outcomes in patients with SCD. Medication adherence is an essential mediator of the clinical benefits of these therapies; low adherence has been shown to increase disease burden and healthcare utilization. This systematic literature review intends to determine the association between adherence to disease\u2010modifying therapies and HRQOL in patients with SCD. <jats:italic>Methods<\/jats:italic>. We found a total of 12 articles involving 788 participants, which included both patients with SCD and caregivers\/parents. Adherence was measured using self\u2010report instruments, laboratory markers, such as fetal hemoglobin and mean corpuscular volume, and mHealth medication trackers. HRQOL was measured using self\u2010report instruments. <jats:italic>Results<\/jats:italic>. All studies demonstrated a correlation between higher HU adherence and better HRQOL scores. Higher HU adherence was associated with lower pain impact, less frequent pain episodes, less fatigue, and improved physical function and mobility, reflecting better physical HRQOL outcomes. Higher adherence was also associated with improved emotional response, decreased anxiety and depressive symptoms, and better social functioning and peer relationships. In addition, our findings indicated that having less frequent barriers to HU adherence was associated with better HRQOL scores. No studies evaluated HRQOL outcomes in relation to adherence to l\u2010glutamine, voxelotor, or crizanlizumab. <jats:italic>Conclusions<\/jats:italic>. Optimizing HU adherence has the potential to improve HRQOL in patients with SCD in addition to reducing healthcare utilization and improving treatment satisfaction. Addressing barriers to HU adherence can positively strengthen the relationship between adherence and HRQOL to potentially improve patient outcomes.<\/jats:p>","DOI":"10.1155\/2022\/2122056","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T23:20:08Z","timestamp":1658186408000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Health\u2010Related Quality of Life and Adherence to Hydroxyurea and Other Disease\u2010Modifying Therapies among Individuals with Sickle Cell Disease: A Systematic Review"],"prefix":"10.1155","volume":"2022","author":[{"given":"Mira","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Elmuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4739-265X","authenticated-orcid":false,"given":"Sherif M.","family":"Badawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"key":"e_1_2_10_1_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijns5020020"},{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510865"},{"key":"e_1_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2009.12.022"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001484"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjhh.2015.02.008"},{"key":"e_1_2_10_6_2","unstructured":"VichinskyE. Overview of variant sickle cell syndromes https:\/\/www.uptodate.com\/contents\/overview-of-compound-sickle-cell-syndromes. Published 2019. Accessed April 15 2021."},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.362"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709113371107"},{"key":"e_1_2_10_9_2","first-page":"558","volume-title":"Sickle Cell Disease","author":"King A. A.","year":"2020"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba3827"},{"key":"e_1_2_10_11_2","unstructured":"VichinskyE. Disease-modifying therapies to prevent pain and other complications of sickle cell disease 2021."},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation.V2012.1.284.3798319"},{"key":"e_1_2_10_13_2","doi-asserted-by":"crossref","unstructured":"Hydroxyurea (hydroxycarbamide) for sickle cell disease 2017.","DOI":"10.1002\/14651858.CD002202.pub2"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903212"},{"key":"e_1_2_10_15_2","first-page":"417","article-title":"Review of medication therapy for the prevention of sickle cell crisis","volume":"43","author":"Riley T. R.","year":"2018","journal-title":"Pharmacy and Therapeutics"},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2009.09.044"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jpepsy\/jsv084"},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21968"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25905"},{"key":"e_1_2_10_20_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-0177"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-017-0713-x"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12878"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.005"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26369"},{"key":"e_1_2_10_25_2","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8296139"},{"key":"e_1_2_10_26_2","doi-asserted-by":"publisher","DOI":"10.1080\/08880018.2018.1505988"},{"key":"e_1_2_10_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2018.01.001"},{"key":"e_1_2_10_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-59"},{"key":"e_1_2_10_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27081"},{"key":"e_1_2_10_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-021-02588-1"},{"key":"e_1_2_10_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27740"},{"key":"e_1_2_10_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2018.01.054"},{"key":"e_1_2_10_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2214.2011.01223.x"},{"key":"e_1_2_10_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28250"},{"key":"e_1_2_10_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1230"},{"key":"e_1_2_10_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26161"},{"key":"e_1_2_10_37_2","doi-asserted-by":"publisher","DOI":"10.2196\/24893"},{"key":"e_1_2_10_38_2","doi-asserted-by":"publisher","DOI":"10.2196\/resprot.6403"},{"key":"e_1_2_10_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0027-9684(15)31419-X"},{"key":"e_1_2_10_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/2333794X19847026"}],"container-title":["BioMed Research International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/bmri\/2022\/2122056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/bmri\/2022\/2122056.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2022\/2122056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:25:56Z","timestamp":1735691156000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2022\/2122056"}},"subtitle":[],"editor":[{"given":"Vida","family":"Demarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1155\/2022\/2122056"],"URL":"https:\/\/doi.org\/10.1155\/2022\/2122056","archive":["Portico"],"relation":{},"ISSN":["2314-6133","2314-6141"],"issn-type":[{"value":"2314-6133","type":"print"},{"value":"2314-6141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"2022-04-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2122056"}}